Patients (~15%) diagnosed with EGFR-mutant NSCLC have a good initial clinical response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR TKIs), but tumor recurrence is common and quick to develop. This evidence concerns the gene EGFR and neoplasm.